<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119314</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000433512</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-000404</secondary_id>
    <secondary_id>CINJ-4735</secondary_id>
    <secondary_id>CINJ-NJ2203</secondary_id>
    <secondary_id>CINJ-5073</secondary_id>
    <nct_id>NCT00119314</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin</brief_title>
  <official_title>Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel&#xD;
      and capecitabine works in treating patients with cancer of unknown primary origin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility of positron emission tomography (PET) and pathology assessment&#xD;
           in identifying the primary tumor site in patients with carcinoma of unknown primary.&#xD;
&#xD;
        -  Determine the efficacy and safety of gemcitabine, docetaxel, and capecitabine in&#xD;
           patients with carcinoma of unknown primary.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the frequency with which PET scan and pathology assessment can define the&#xD;
           organ of origin in these patients.&#xD;
&#xD;
      OUTLINE: This is a 2-part, multicenter study.&#xD;
&#xD;
        -  Part 1: Patients undergo a comprehensive standard evaluation, including pathologic&#xD;
           assessment and positron emission tomography scan, to attempt to identify the primary&#xD;
           tumor site. If the primary tumor site is identified, the patient proceeds to appropriate&#xD;
           treatment for that tumor off study. If the primary tumor site remains unknown, the&#xD;
           patient proceeds to chemotherapy in part 2 of the study.&#xD;
&#xD;
        -  Part 2: Patients receive gemcitabine IV and docetaxel IV over 30 minutes on days 4 and&#xD;
           11. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat&#xD;
           every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks and then every 6&#xD;
      months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 44 patients (10-29 for part 2) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Carcinoma of Unknown Primary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy for which no primary origin has&#xD;
             been identified despite routine workup, including the following:&#xD;
&#xD;
               -  History and physical examination&#xD;
&#xD;
               -  Chemistry profile and other blood work, including tumor markers with follow up on&#xD;
                  any positive findings&#xD;
&#xD;
               -  CT scan or MRI of the chest, abdomen, and pelvis&#xD;
&#xD;
               -  Mammography (for female patients)&#xD;
&#xD;
               -  Prostate examination (for male patients)&#xD;
&#xD;
               -  Stool guaiac&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Previously irradiated lesions are not considered measurable disease unless there&#xD;
                  is documented clear tumor progression in these lesions after completion of&#xD;
                  radiotherapy&#xD;
&#xD;
          -  The following tumor types or presentations are excluded:&#xD;
&#xD;
               -  Resectable disease&#xD;
&#xD;
               -  Tumors consistent with germ cell primary, as indicated by any of the following:&#xD;
&#xD;
                    -  Midline tumor&#xD;
&#xD;
                    -  Elevated beta human chorionic gonadotropin&#xD;
&#xD;
                    -  Elevated alpha-fetoprotein&#xD;
&#xD;
                    -  i12p chromosomal alteration&#xD;
&#xD;
               -  Prostate primary with elevated prostate-specific antigen&#xD;
&#xD;
               -  Females with axillary nodes as the primary disease site&#xD;
&#xD;
               -  Tumors limited to the peritoneal cavity consistent with primary peritoneal&#xD;
                  carcinoma&#xD;
&#xD;
               -  Neuroendocrine tumors&#xD;
&#xD;
               -  Squamous cell carcinoma involving cervical or inguinal lymph nodes&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
               -  Prior brain metastases allowed provided patient completed definitive treatment&#xD;
                  with brain irradiation with or without resection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Granulocyte count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Alkaline phosphatase (AP) normal AND AST and ALT ≤ 5 times upper limit normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN&#xD;
&#xD;
               -  AP ≤ 5 times ULN AND AST and ALT normal&#xD;
&#xD;
          -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Intestinal absorption intact&#xD;
&#xD;
               -  No uncontrolled diarrhea and/or daily emesis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ of the cervix or basal cell skin cancer&#xD;
&#xD;
          -  No severe medical or psychiatric illness that would preclude study treatment&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for this malignancy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  Prior palliative radiotherapy to areas of bony metastases allowed provided there is&#xD;
             measurable disease outside the radiotherapy port&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent antiviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A. Poplin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at the Mountainside Hospital</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carol G. Simon Cancer Center at Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Group</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902-0220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <name_title>Elizabeth Poplin, MD</name_title>
    <organization>UMDNJ/CINJ</organization>
  </responsible_party>
  <keyword>newly diagnosed carcinoma of unknown primary</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

